Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108987 | 0.91 | HTR7 (0.66) | HTR7POLBAPEX1TDP1NPC1 | |
| SCHEMBL1258171 | 0.87 | HTR7 (0.59) | HTR7NPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL25405722 | 0.84 | KMT2A (0.49) | NPC1RAB9ASMN1; SMN2KMT2ALMNA | |
| SCHEMBL21191659 | 0.84 | HDAC1 (0.47) | POLBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3966037 | 0.80 | NPC1 (0.60) | HTR7POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2490498 | 0.79 | HTR7 (0.78) | HTR7NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL26584242 | 0.78 | NPC1 (0.82) | HTR7NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL15221192 | 0.78 | MLYCD (0.67) | HTR7POLBAPEX1TDP1RAB9A | |
| Hydrochloric Acid SCHEMBL10578417 | 0.77 | HTR7 (0.75) | HTR7NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL28988600 | 0.76 | HTR7 (0.68) | HTR7NPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061083-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATGON (KR) | 2026-03-05 | — | — | US | disclosed |
| US-12491271-B2 | Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-12-09 | — | — | US | disclosed |
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-05-16 | — | — | US | disclosed |
| EP-3741392-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | Seoul National University R & DB Foundation (KR) | 2020-11-25 | — | — | EP | disclosed |
| US-20200345870-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2020-11-05 | — | — | US | disclosed |
| WO-2019143016-A9 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | 서울대학교산학협력단 | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061083-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, FABP7, SLC46A1 | HTR7 1032/4885POLB 4372/4885APEX1 4345/4885 |
| US-12491271-B2 | Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor | TSPO, FABP7, SLC46A1 | HTR7 772/4885POLB 4484/4885APEX1 3982/4885 |
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, FABP7, SLC46A1 | HTR7 772/4885POLB 4484/4885APEX1 3982/4885 |
| US-20200345870-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, TMEM14C, FABP7 | HTR7 1191/4885POLB 4522/4885APEX1 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.